Utah has become the first U.S. state to authorize an AI startup, Nolla Health, to issue automated prescriptions for acne treatments with only minimal human supervision, marking a pioneering step in healthcare automation.
- First approved U.S. AI system to issue prescriptions end-to-end
- Three-stage pilot with increasing AI autonomy for acne treatment
- Plans to expand AI prescribing to other conditions after pilot
What happened
The pilot program is structured into three phases: initially, every AI-generated prescription must be reviewed and approved by a physician. After demonstrating safety with at least 100 patients, the AI will independently issue prescriptions for 500 patients with physicians providing retrospective reviews. Finally, human clinicians will audit a minimum of 10% of prescriptions monthly as the AI gains near-full autonomy in prescribing. The pilot operates under the regulatory framework of Utah's AI Learning Lab sandbox program.
Why it matters
This milestone reflects a significant advancement in healthcare delivery, introducing the first end-to-end AI doctor model authorized to make prescribing decisions without routine initial physician involvement. It could pave the way for more accessible, efficient care for common conditions by reducing wait times and dependency on in-person doctor visits. The careful phased rollout with layered oversight ensures that patient safety and quality of care remain priorities while exploring AI’s potential.
Nolla Health’s approach focuses on simple, well-understood conditions that can be effectively treated with topical medications, establishing a controlled environment for AI involvement in healthcare. This initiative may serve as a blueprint for AI regulatory frameworks nationwide and globally, illustrating how emerging technologies can be responsibly integrated into medical practice with clear guardrails and collaborative physician oversight.
What to watch next
Stakeholders should monitor the pilot outcomes, particularly around patient safety, efficacy of AI-prescribed treatments, and patient acceptance of an AI-driven service. The transition from physician-approved to autonomous AI prescribing will be a critical phase that demonstrates whether the technology is viable for broader application. Observers should also watch for regulatory responses in other states or countries following Utah’s lead.
Looking ahead, Nolla Health plans to expand automated prescriptions beyond acne to other common conditions such as influenza and uncomplicated urinary tract infections, which can be assessed remotely with objective tests and straightforward treatment protocols. The success or challenges of this pilot will likely influence the pace and scope of AI adoption in routine clinical care, potentially transforming access to healthcare over the next decade.